" class="no-js "lang="en-US"> Coen Maas - Medtech Alert
Saturday, June 14, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Coen Maas

Coen Maas

About Coen Maas

Rare dangerous diseases are rewarding to investigate – it is exciting work. I believe that the lessons learned from these extreme and sometimes misunderstood conditions can be directly extrapolated to more prevalent diseases, including stroke, atherosclerosis, diabetes, and Alzheimer’s disease.

• Proud winner of the 2021 NVTH quiz (eternal glory ;)
• 96 publications (3750 cites; H-index 33; RCR 2.3)
• Principal supervisor of 3 completed doctoral theses; 5 ongoing (IUS Promovendi since 2021)
• 2 patents
• 50+ Invited presentations

Related Story

Fundraising

 TargED Biopharmaceuticals Raises EUR 39 Million in Series A Financing to Bring Groundbreaking Thrombolytic Treatment to Patients | Pharmtech Focus

TargED Biopharmaceuticals Raises EUR 39 Million in Series A Financing to Bring Groundbreaking Thrombolytic Treatment to Patients

February 22 2022

TargED Biopharmaceuticals (“TargED”), a private biotechnology company focused on developing improved treatments for thrombotic diseases, […]